1970s
Yancopoulos said Nobel Prize winners Michael Brown and Joseph Goldstein, members of Regeneron's board, have worked together since the 1970s.
“Brown and Goldstein, Nobel Prize winners that have been working together since the 70s.”
Topic
13 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
1970s
Yancopoulos said Nobel Prize winners Michael Brown and Joseph Goldstein, members of Regeneron's board, have worked together since the 1970s.
“Brown and Goldstein, Nobel Prize winners that have been working together since the 70s.”
2017
As of the interview, Regeneron Pharmaceuticals had six FDA-approved drugs and was described as the third best-performing stock in the S&P 500 over the prior decade.
“The company has developed six FDA-approved drugs so far, and it's the third best-performing stock in the S &P 500 over the past decade.”
2017
Regeneron Pharmaceuticals had two manufacturing plants, one in Rensselaer, New York and one in Limerick, Ireland.
“where we now have two plants, one up at Ronsolier and one in Ireland, in Raheem in Ireland.”
2017
Regeneron Pharmaceuticals announced an initiative to sequence the exomes of the 500,000-person UK Biobank.
“We just recently announced a major initiative where we're going to be sequencing the UK biobank of 500 ,000 people.”
2017
Yancopoulos said Dupixent launched in atopic dermatitis, a field with no other biologics.
“we priced in a brand new space. There was no other biologics for atopidermatitis.”
2017
Yancopoulos said Dupixent was priced at less than half the average price of psoriasis drugs.
“we price our drug at less than half the price of the average psoriasis drugs just because we think it's the appropriate thing to do.”
2017
Yancopoulos said Regeneron Pharmaceuticals had 250 interns in the summer of the interview, and the head of the Regeneron Genetics Center began as an intern.
“I think that this summer we had 250 interns.”
2023
Amgen's injectable PCSK9 drug has passed $1 billion in annual sales, while Regeneron's has not, according to Meg Terrell.
“I mean, the Amgen drug has surpassed $1 billion in annual sales. The Regeneron one hasn't.”
Undated
Regeneron Pharmaceuticals had an important collaboration with Medarex, a company that also developed human antibody mice.
“And we actually collaborated. We had an important collaboration with Medarex.”
Undated
Yancopoulos said Len Schleifer helped create a business plan for Regeneron to stay independent, unlike other antibody companies that aimed to be acquired.
“he helped create a business plan and structure where we would stay independent. Whereas a lot of these other companies, their goal was to sort of get bought out.”
Undated
Yancopoulos said Regeneron's first drug approval was its IL-1 trap for cold-induced inflammatory syndrome, which he described as an early example of going from a human genetic disease to a blocking biologic.
“Our first drug approval, which is our IL-1 trap or ARKELIST in cold-induced inflammatory syndrome, was perhaps the first example”
Undated
Yancopoulos said the IL-1 trap produced an 85 percent average improvement in patients with cold-induced inflammatory syndrome.
“85 % average improvement in a horrific disease. That's how you want genes to work.”
Undated
Yancopoulos said Regeneron's PCSK9 antibody was the first approved anti-PCSK9 agent for lowering cholesterol, building on gene discoveries by Helen Hobbs and Jonathan Cohen at UT Southwestern.
“where we got the first approved anti-PCSK9 agent for lowering cholesterol”
Episodes